Welcome to our dedicated page for Precigen news (Ticker: PGEN), a resource for investors and traders seeking the latest updates and insights on Precigen stock.
Precigen, Inc. (Nasdaq: PGEN) is a pioneering biopharmaceutical company dedicated to discovering and developing next-generation gene and cellular therapies in the United States. Specializing in disease-modifying therapeutics, Precigen has been at the forefront of genetic engineering and synthetic biology solutions. The company excels in creating innovative therapies for some of the most challenging diseases in areas such as immuno-oncology, autoimmune disorders, and infectious diseases.
Precigen's core technologies include:
- UltraVector® Platform: This platform incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs.
- UltraCAR-T® Cell Therapies: These therapies address limitations of conventional CAR-T therapies by improving in vivo CAR-T expansion and persistence, adding safety features, and reducing manufacturing costs.
- AdenoVerse™ Technology Platform: A library of engineered adenovector serotypes, including gorilla adenovectors, which is used for gene delivery, and modulating immune responses.
- RheoSwitch® Inducible Gene Switch: This technology allows for precise control over gene expression, making therapies safer and more efficient.
Recent achievements include the Phase 2 pivotal study data for PRGN-2012 in treating recurrent respiratory papillomatosis (RRP), a rare and debilitating disease. The study showcased promising results, with 51% of patients achieving Complete Response, defined as no need for surgical interventions in the 12-month period following treatment.
Precigen is also actively developing UltraCAR-T therapies, which have demonstrated significant preliminary efficacy and safety advantages over existing CAR-T therapies. These therapies are currently being evaluated in clinical trials for various hematological and solid tumors.
Financially, Precigen has shown resilience, focusing on sound fiscal management while advancing its clinical pipeline. Despite experiencing fluctuations in research expenses and revenues, the company remains committed to achieving its milestones and maintaining a strong balance sheet.
Precigen's business model involves commercializing its technologies through collaborations with industry partners who possess specialized expertise, development resources, and sales capabilities. This collaborative approach enables Precigen to bring new and improved products to market efficiently.
For the latest updates on Precigen's innovative gene and cell therapies, visit their official website and follow them on social media platforms like X (formerly Twitter), LinkedIn, and YouTube.
Precigen (Nasdaq: PGEN) held a virtual R&D event on Dec. 15, 2020, showcasing significant advancements in its clinical pipeline. Key updates include:
- PRGN-3005 UltraCAR-T: First clinical data reported with promising results in ovarian cancer showing 50% tumor regression among patients.
- PRGN-3006 UltraCAR-T: Positive data in acute myeloid leukemia (AML) with effective treatment responses.
- AG019 ActoBiotics: Demonstrated safety and potential in stabilizing C-peptide levels in Type 1 diabetes patients.
These results mark critical milestones for the company, indicating progress in innovative gene and cell therapies.
Precigen, a biopharmaceutical company (Nasdaq: PGEN), announced a virtual event on December 15, 2020, at 11:00 AM ET, to update stakeholders on its clinical pipeline. The event will feature data from key programs, including PRGN-3005 and PRGN-3006 UltraCAR-T, as well as AG019 ActoBiotics. Executives and leading investigators will participate, presenting advancements in the company's innovative gene and cell therapies targeting serious diseases. Registration is available via the investor relations website.
Precigen announced new data from its PRGN-3006 UltraCAR-T® phase 1/1b study for treating relapsed or refractory acute myeloid leukemia (AML) at the 62nd ASH Annual Meeting. The study shows promising results, with six patients treated and no dose-limiting toxicities reported. A 100% manufacturing success rate using their proprietary process was achieved. The UltraCAR-T cells demonstrated encouraging expansion and persistence in patients, with one case study showing robust cell activity seven months post-infusion. These advancements suggest a potential improvement over existing CAR-T therapies.
On November 16, 2020, Precigen (Nasdaq: PGEN) announced the successful dosing of the first patients with UltraCAR-T cells made using its proprietary UltraPorator system, which aims to revolutionize the manufacturing of personalized cancer therapies. The patients participated in two Phase 1 clinical trials: PRGN-3005 for advanced ovarian cancer and PRGN-3006 for relapsed acute myeloid leukemia. This innovation streamlines manufacturing, allowing for rapid cell production within medical facilities and timely patient treatment.
Precigen, Inc. (Nasdaq: PGEN) reported third quarter 2020 revenues of $23.6 million, up 29% from $18.3 million in Q3 2019. The net loss narrowed to $29.5 million or $(0.18) per share, improving from $49.1 million or $(0.32) per share a year prior. Year-to-date revenues reached $83.8 million, a 14% increase from $73.7 million in 2019. Key achievements included FDA clearance for the UltraPorator system, dosing the first patient in the PRGN-2009 trial, and advancing UltraCAR-T therapies for ovarian cancer and AML.
Precigen, a biopharmaceutical company, will release its third quarter 2020 financial results on November 9, 2020. The company focuses on developing gene and cell therapies for various diseases, including cancer and autoimmune disorders. In early December, Precigen plans to host a call to update stakeholders on its clinical pipeline. The firm emphasizes its commitment to precision medicine and aims to innovate in affordable biotherapeutics. Investors should stay tuned for financial performance insights and clinical progress in the upcoming announcements.
Precigen, Inc. (Nasdaq: PGEN) has appointed Gaurav Vij as the new head of business development. Mr. Vij, with over 18 years of experience, will focus on accelerating strategic partnerships and enhancing the company’s pipeline programs. His prior experience includes significant roles at Gilead Sciences, Amgen, and Shire Pharmaceuticals, with a strong emphasis on oncology. This appointment aligns with Precigen's strategy to maximize value through partnerships and foster innovation in gene and cell therapies.
Precigen (Nasdaq: PGEN) has received FDA clearance for its UltraPorator system, designed for rapid manufacturing of UltraCAR-T therapies. This system enables efficient clinical trial manufacturing for PRGN-3005 and PRGN-3006, targeting ovarian cancer and acute myeloid leukemia, respectively. The technology transfer is now complete, allowing personalized therapy delivery to patients. The UltraPorator significantly reduces processing time and contamination risks compared to traditional methods, enhancing the scalability of CAR-T therapy production. This advancement aims to transform patient access to critical cancer treatments.
On October 9, 2020, Precigen (Nasdaq: PGEN) announced that Merck KGaA, Darmstadt, Germany, increased its ownership from 11.6% to 14.8% by converting a $25 million convertible note. This move positions Merck as Precigen's second-largest shareholder. The agreement includes the reassignment of CAR-T development rights, allowing Precigen to regain autonomy over its proprietary CAR-T technology in exchange for $150 million in stock and the convertible note. Two UltraCAR-T therapies are currently in Phase 1 trials against ovarian cancer and AML.
On September 8, 2020, Precigen (Nasdaq: PGEN) announced that Helen Sabzevari, PhD, President and CEO, will present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020, at 10:30 AM ET. The event will be accessible via a live webcast through Precigen’s website. Precigen focuses on innovative gene and cell therapies to address serious diseases in immuno-oncology, autoimmune disorders, and infectious diseases, advancing its clinical pipeline toward commercialization.
FAQ
What is the current stock price of Precigen (PGEN)?
What is the market cap of Precigen (PGEN)?
What does Precigen, Inc. specialize in?
What are some of Precigen's core technologies?
What are the key areas of focus for Precigen's therapies?
What recent achievements has Precigen made?
How does Precigen commercialize its technologies?
What makes UltraCAR-T® Cell Therapies unique?
What is the AdenoVerse™ Technology Platform?
Where can I find more information about Precigen's latest updates?
What financial strategies does Precigen employ?
What is the RheoSwitch® Inducible Gene Switch?
